Zamtocabtagene autoleucel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Zamtocabtagene autoleucel Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Zamtocabtagene autoleucel can convert its Autologous CAR-T profile and CD19 x CD20 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Zamtocabtagene autoleucel (query alias: Zamtocabtagene autoleucel) |
|---|---|
| Modality / target | Autologous CAR-T; CD19 x CD20; CD19 inhibitors, CD20 inhibitors, T lymphocyte replacements |
| Highest global status | Phase 2 |
| Originator | Miltenyi Biomedicine GmbH |
| Active developers | Miltenyi Biomedicine GmbH, National Institute For Health & Care Research, Miltenyi Biotec BV & Co. KG |
The MCP disease footprint includes Carney Complex, Refractory Mature B-Cell Non-Hodgkin Lymphoma, Diffuse large B-cell lymphoma recurrent. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07569965 | Phase 2 | Not yet recruiting | 52 | Progression-free survival (PFS) |
| NCT07288879 | Phase 2 | Recruiting | 31 | Objective Response Rate |
| NCT07178431 | Phase 1/2 | Recruiting | 26 | Primary endpoints Phase I |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
ZAMTOCABTAGENE AUTOLEUCEL, A TANDEM CD20-CD19 DIRECTED CAR-T CELL THERAPY IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: CROSSOVER ANALYSIS (THIRD-LINE) FROM THE RANDOMIZED, PIVOTAL DALY 2-EU TRIAL
Phase 2; n=168; evaluation: Positive. Reported fields: BOR = 79.3 %
68Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: Adverse Event: CRS = 32 pts (46.4%) experienced cytokine release syndrome (CRS), all grade 1-2
BISPECIFIC ANTI-CD20/19 CAR-T ¨C ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL ¨C INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY
Not Applicable; n=28; evaluation: not stated. Reported fields: CR = 50 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Zamtocabtagene autoleucel addresses Carney Complex, Refractory Mature B-Cell Non-Hodgkin Lymphoma, Diffuse large B-cell lymphoma recurrent. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Autologous CAR-T—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 146 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CD19 x CD20 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-07-30 | Curocell partners with Biruni to seek Türkiye approval for RIMQARTO in 2027 | Approved | Financial terms not disclosed |
| 2026-07-29 | Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset | Preclinical | US$465.0M upfront; US$2,720.0M milestones |
| 2026-07-21 | Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T | Preclinical | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 3 August 2026. Counts and status fields may change as source records update.
